President Samia’s policy approach to healthcare defines domestic policy success. Since President Benjamin Mkapa’s third ...

Oppama used to produce the Bluebird, once one of Nissan’s best known cars and sold as the Altima in the United States. Now it makes the smaller Note and Aura models. Nissan is Yokosuka’s top ...

In the past, British hands have assembled models such as the Bluebird, Primera, Micra and Almera. But last month, Alan Johnson, senior vice president for manufacturing for Nissan's Africa ...

Bluebird Bio, Inc. (NASDAQ:BLUE) shares are trading higher on Wednesday following the news that Bluebird Bio, Carlyle, and SK Capital Partners, LP, have amended their definitive agreement.

Bluebird bio shareholders have dragged their feet in tendering shares as part of the company’s sale process, prompting buyers Carlyle and SK Capital to extend their offer deadline once again.

Joshua Cohen is a Boston-based writer who covers health policy. Bluebird bio is a highly innovative biotechnology company which develops gene therapies for several rare genetic disorders and cancers.

Nissan on May 13 announced sweeping cuts across the company with plans to lay off another 11,000 employees and close more than a half-dozen plants across the globe. The latest cuts bring the ...

For investors in gene therapy biotech bluebird bio, a wait-and-see approach toward a proposed acquisition has paid off. In a revised merger agreement, Carlyle and SK Capital Partners are now ...

Japanese carmaker Nissan has increased its planned job cuts by 11,000 as part of its recovery plan "Re-Nissan." The company now plans to slash a total of 20,000 positions by 2027. The company ...

Under the terms of the amended agreement, Bluebird stockholders can elect to receive either the original offer of $3.00 per share in cash plus a contingent value right (CVR) of $6.84 per share in ...